CRYOIMMUNOTHERAPY
CRYO + IMMUNOTHERAPY
Cryoablation releases tumour antigens into an immunologically active context — when combined with checkpoint inhibitors, this can prime a systemic anti-tumour immune response that reaches lesions beyond the treated site.
analyticsAt a Glance
- check_circleCryoablation releases intact tumour antigens and DAMPs that activate dendritic cells and cytotoxic T-cells
- check_circleAnti-CTLA-4 + cryoablation combinations have shown abscopal responses in melanoma and RCC clinical studies
- check_circleOngoing trials evaluating cryoimmunotherapy in NSCLC, breast, prostate, and colorectal cancer
- check_circleCombination regimens available at immunotherapy-capable oncology centres in China via CancerFax
What Is Cryoimmunotherapy and How Does It Work?
Standard cryoablation destroys the treated tumour lesion locally. But unlike heat-based ablation, which denatures proteins, the controlled freeze-thaw cycle of cryoablation releases intact tumour antigens — including neoantigens specific to each patient's tumour — into the surrounding tissue environment alongside danger signals that alert the immune system.
“Cryoablation creates the antigen release of a tumour vaccine; checkpoint inhibitors remove the brakes that stop the immune system from acting on it.”
Immunogenic Cell Death
Freeze-thaw cycles cause tumour cells to release damage-associated molecular patterns (DAMPs) — calreticulin, HMGB1, and ATP — that activate dendritic cells. These dendritic cells uptake and present tumour antigens to T-cells, initiating a primed anti-tumour immune response.
Checkpoint Inhibitors Remove Immune Suppression
Anti-CTLA-4 (ipilimumab) broadens the T-cell repertoire activated by the vaccine-like antigen release. Anti-PD-1/PD-L1 agents (nivolumab, pembrolizumab) restore effector function in exhausted T-cells within the tumour microenvironment, enabling systemic immune attack on untreated lesions.
Key Clinical Data Points
Clinical evidence for cryoimmunotherapy is at an earlier stage than for single-modality cryoablation, but early signals are promising across multiple tumour types.
- ~27%Abscopal response rate in RCC (Phase II)Reported by Kato et al. in a Phase II study of cryoablation + ipilimumab in metastatic RCC — distant unablated lesions showed objective responses.
- >40Active clinical trials in cryoimmunotherapy (2024–2025)Registered trials across NSCLC, melanoma, breast, prostate, and colorectal cancer exploring various checkpoint inhibitor and cryoablation combinations.
- 6–8×Increase in tumour-infiltrating T-cells post-cryoPreclinical and translational data consistently show 6–8-fold increases in CD8+ T-cell infiltration in untreated lesions after cryoablation + checkpoint blockade.
- Day 1–3Timing window for checkpoint inhibitor dosingMost combination protocols administer the first checkpoint inhibitor dose within 72 hours of cryoablation to coincide with peak antigen release and dendritic cell activation.
The Abscopal Effect: Treating Distant Tumours Through Local Ablation
The abscopal effect refers to regression of untreated tumour lesions at sites distant from a locally treated tumour — a phenomenon observed rarely after radiotherapy but potentially amplified when cryoablation is combined with checkpoint inhibitors.
“When cryoablation's in-situ vaccine effect meets checkpoint inhibitor-liberated T-cells, the immune system can attack the entire tumour burden — not just the frozen lesion.”
Why Cryoablation Potentiates the Abscopal Effect Better Than Heat
RFA and microwave ablation denature proteins at >60°C, reducing antigenicity of released tumour debris. Cryoablation's lower temperatures (–40°C to –150°C) preserve protein structure and antigenicity, producing superior dendritic cell activation in preclinical comparison studies.
Clinical Evidence: Melanoma and RCC
In a published Phase II study combining cryoablation with ipilimumab in metastatic RCC, 27% of patients achieved objective responses in unablated lesions — a direct demonstration of the abscopal effect. Similar abscopal responses have been reported in melanoma series combining cryo with anti-PD-1 therapy.
Ongoing Investigation: Breast, NSCLC, Prostate
Multiple ongoing trials are evaluating cryoimmunotherapy in triple-negative breast cancer (cryo + pembrolizumab), stage III NSCLC (cryo + nivolumab), and castration-resistant prostate cancer (cryo + ipilimumab). Results from these trials are expected to define combination protocols more precisely.
How a Cryoimmunotherapy Protocol Is Structured
The sequence and timing of cryoablation relative to checkpoint inhibitor dosing is critical to maximising the immunological synergy between the two modalities.
- 1
Baseline Assessment
PD-L1 expression, tumour mutational burden, and baseline imaging are assessed to select the most appropriate checkpoint inhibitor and identify target and sentinel lesions.
- 2
Checkpoint Inhibitor Induction
In some protocols, 1–2 doses of anti-CTLA-4 or anti-PD-1 are administered before cryoablation to pre-activate the immune system and expand the T-cell compartment.
- 3
Cryoablation of Index Lesion
The dominant or most accessible lesion is targeted for cryoablation, chosen to maximise antigen release while minimising procedural risk. Incomplete ablation may be intentional — leaving viable tumour at the periphery to maximise antigen contact with immune cells.
- 4
Immediate Checkpoint Inhibitor Dosing
The first (or next) checkpoint inhibitor infusion is administered within 24–72 hours of cryoablation to exploit the window of peak antigen presentation and dendritic cell activation.
- 5
Continuation of Systemic Immunotherapy
Checkpoint inhibitors continue on their standard dosing schedule (every 2–6 weeks depending on agent). Additional lesions may be cryoablated in subsequent cycles if the systemic response is incomplete.
- 6
Response Assessment
PET-CT or multiphasic CT at 8–12 weeks evaluates both the treated lesion and distant untreated sites for abscopal immune response.
Published Clinical Evidence by Tumour Type
The following represents key published studies and ongoing trials in cryoimmunotherapy across major tumour types as of 2025.
| Tumour Type | Combination | Phase / Design | Key Finding |
|---|---|---|---|
| Renal Cell Carcinoma | Cryoablation + Ipilimumab | Phase II (Kato et al.) | 27% abscopal response in unablated lesions; 7.4% CR rate |
| Melanoma | Cryoablation + Anti-PD-1 | Pilot / Prospective series | T-cell infiltration increased in untreated lesions; objective responses in 3/12 patients |
| NSCLC | Cryoablation + Nivolumab | Phase I/II (ongoing) | Early data show disease control in 60% at 6 months; formal results pending |
| Triple-Negative Breast CA | Cryoablation + Pembrolizumab | Phase II (ongoing) | Neoadjuvant combination; pCR rate assessment at primary endpoint |
| Prostate Cancer (CRPC) | Cryoablation + Ipilimumab | Phase II (Alliance trial) | PSA responses in 8/19 patients; immune activation confirmed by T-cell assay |
| Colorectal (liver mets) | Cryoablation + Anti-PD-L1 | Translational / pilot | Increased TIL density in untreated lesions post-combination; ORR data maturing |
Potential Benefits vs Current Limitations
Cryoimmunotherapy represents a compelling rational combination, but the clinical evidence base is still maturing relative to monotherapy cryoablation or standard checkpoint inhibitor regimens.
Potential Benefits
- Systemic anti-tumour response from local procedureA single cryoablation session can, in responsive patients, trigger immune control of metastatic lesions at multiple distant sites.
- Personalised in-situ vaccineUnlike off-the-shelf vaccines, cryoimmunotherapy uses the patient's own tumour antigens — automatically targeting neoantigens unique to their cancer.
- Synergy with standard immunotherapy schedulesCryoablation can be added to existing checkpoint inhibitor cycles without requiring treatment interruption or dose modification.
- Potential to convert immunotherapy non-respondersPatients whose tumours are immunologically 'cold' may become responsive to checkpoint inhibitors after cryoablation increases intratumoural immune infiltration.
Current Limitations
- Limited Phase III evidenceMost cryoimmunotherapy data are from Phase I/II trials and retrospective series. No Phase III RCT has yet established an overall survival benefit for any tumour type.
- Optimal sequencing not yet definedWhether to give checkpoint inhibitors before, simultaneously, or after cryoablation — and how many cycles — varies across protocols and requires further study.
- Not all patients respond systemicallyThe abscopal effect, while documented, occurs in a minority of patients. Predictive biomarkers for systemic response have not been validated.
- Combined toxicity profileAdding cryoablation to immunotherapy does not substantially increase adverse events, but procedural complications and immune-related adverse events both require coordinated management.
More from the Cryoablation Therapy Resource Library
Continue exploring cryoablation — from the foundational science to disease-specific clinical applications.
- Cryoablation Therapy — Complete Treatment Guide
- Cryoablation for Bone Metastases: Pain Control and Local Treatment
- Cryoablation for Liver Tumours: HCC and Metastases
- Cryoablation for Lung Cancer and Pulmonary Lesions
- Cryoablation for Breast Cancer and Breast Fibroadenoma
- Cryoablation for Kidney Cancer: Renal Cell Carcinoma
Frequently Asked Questions
Common questions from patients exploring cryoimmunotherapy as part of their treatment strategy.
About Cryoimmunotherapy
Who is a good candidate for cryoimmunotherapy?
Patients most likely to benefit are those with metastatic cancer who have at least one accessible lesion suitable for cryoablation, are either naive to checkpoint inhibitors or have partial responses, and have tumours with some degree of immune infiltration. Tumour types with the strongest current evidence include renal cell carcinoma, melanoma, and NSCLC. CancerFax can review your specific pathology and treatment history to assess whether a cryoimmunotherapy combination is appropriate for your case.
Does cryoimmunotherapy work better than checkpoint inhibitors alone?
This question is still being answered in ongoing Phase II/III trials. Existing data suggest that cryoablation can enhance checkpoint inhibitor efficacy — particularly in patients with 'cold' tumours (low baseline T-cell infiltration) — by increasing the number and diversity of tumour-specific T-cells available to be activated by immunotherapy. Whether this translates to improved overall survival versus immunotherapy alone will require mature randomised trial data.
Can I receive cryoimmunotherapy if I am already on pembrolizumab?
Yes. Adding cryoablation to an ongoing pembrolizumab or nivolumab regimen is feasible without interrupting systemic treatment. Many combination protocols are designed exactly this way — identifying a patient on checkpoint inhibitor therapy who has oligoprogression in one or more lesions and adding cryoablation as a local consolidation strategy to boost the systemic immune response.
Where in China can I access cryoimmunotherapy combination treatment?
Several major Chinese oncology centres — including Cancer Hospital Chinese Academy of Medical Sciences (CAMS), Peking University Cancer Hospital, and Sun Yat-sen University Cancer Center — have active interventional oncology and immunotherapy programmes capable of delivering combined cryoimmunotherapy. CancerFax facilitates referrals, pre-treatment consultations, and care coordination at these centres for international patients.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Explore Cryoimmunotherapy for Your Cancer
CancerFax reviews your tumour type, immunotherapy history, and current systemic therapy to assess whether a cryoablation plus checkpoint inhibitor combination strategy is appropriate — and connects you with specialist immuno-oncology centres in China and India.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.